We are pleased to invite you to Inhalation and Respiratory Drug Products European Conference 2018 that will be held in Barcelona, Spain on 7-8 June 2018. The conference will bring together specialists from Medical, Pharmacology and Health Care industries. You will have possibility to discuss about the modern issues of the respiratory drug delivery systems, new technologies, innovation and perspectives of therapeutic fields.

Who should attend:

Medical suppliers
Inhalation therapists
Inhaler technique trainers
Medical research scientists
Home healthcare providers
Regulatory affairs managers
Inhalation product developers
Dry powder inhalation specialists
Drug quality and design specialists
Medical marketing representatives
Respiratory drug delivery specialists
Lungs and airway disorder specialists
Senior research fellows and professors
Control, support and testing specialists
Finished product release testing specialists
Asthma, allergy and immunology specialists
Head specialists of respiratory drug delivery products
Inhalation and respiratory drug device engineering technologists

Industries: Medical Marketing, Marketing and Business Development, Medical Devices & Injectors, Inhalation Product Development, Respiratory Drug Development, Respiratory medicine Inhalation, Inhalation Development and Engineering, Drug Delivery Innovation Respiratory Pharmacology, Device Engineering New Delivery Technologies, Inhaled Dosage Systems Connective Health, Respiratory Regulations Respiratory R&D, Pulmonary Disease Metered Dose Inhaler Development, Scientific Research, Generics & Respiratory.

Key Points:

• Analytical approaches and specifications
• Target Quality Product Profile consideration
• Overview of the available liquid inhalation devices
• Challenges and opportunities of inhaler models on the market
• Advantages of large and small molecules for inhaled therapy
• The future potential of soft mist inhaler for high dose applications
• The new approaches of therapeutic fields for length cancer


To discuss the attendee opportunities or register for the event please contact:
Teo Davitashvili
Conference producer
Tel.: +420 226 633 309
E-mail address:

Event Speakers

Dr. John N. Pritchard

Director PMO and Technology, Respiratory Drug Delivery


Dr. Carsten Ehrhardt

Professor in Pharmaceutics

Trinity College Dublin

Paul Johnson

Former GSK Respiratory Franchise Senior Director

Director Pau Johnson Consulting Limited

Prof, Dr. Sven Stegemann



Iris Erez

Former Teva / Trial-In Pharma LTD

Director of respiratory segment

Christina Gkousgkouni

Brand Manager Xolair Severe Allergic Asthma


Wilbur de Kruijf

Inhaler development


Dr. Frank Thielmann

PMO & Operational Excellence Platform Leader, Biologics


Dr. Joachim Eicher

Senior Executive

Boehringer Ingelheim

  • Dr. John N. Pritchard
    A graduate in physics from Birmingham University, John joined the UK Atomic Energy Authority in 1977, leading research into the deposition and clearance of particles in the respiratory tract. During this time he gained a PhD from the University of Essex on research into the lung deposition of tar from cigarette smoking. John moved into the pharmaceutical industry in 1991, initially with Glaxo, then with 3M and AstraZeneca. At different stages in his career he held roles in line management, project leadership, technology development and commercial product strategy. During this time, he has been associated with the launch or life-cycle management of 11 different inhaled marketed products. Since January 2011, John has been Chief Technology Officer for Philips Respironics Drug Delivery, with global accountability for the development of advanced delivery systems for the monitoring and treatment of respiratory diseases. John has published widely in the respiratory drug delivery field, been editor to several journals, as well as having served as President of The Aerosol Society, Board Member for the International Society for Aerosols in Medicine and on the UK Government Committee on the Medical Effects of Airborne Pollutants. He is currently a member of the United Nations Medical Technical Options Committee, which makes recommendations on the essential use of CFC propellants, is an editor for Pharmaceutical Technology. Until 2015 when they were acquired, he was also a member of the Scientific Advisory Board of Prosonix.
  • Dr. Carsten Ehrhardt
    Trinity College Dublin
    Carsten Ehrhardt is Professor in Pharmaceutics at the School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin. In addition, he is holding an Adjunct Professorship at the School of Pharmacy, University of Southern California. Carsten was elected Fellow of Trinity College Dublin in 2013. Carsten obtained his Ph.D. in Biopharmaceutics from Saarland University in 2003. His research efforts are focused on lung drug disposition, pulmonary epithelial transport and molecular origins of airways disease. He has edited 1 book and (co-)authored 83 peer-reviewed publications, 11 book chapters and more than 230 abstracts and conference proceedings. Carsten has given over 120 invited oral presentations. He is the proud recipient of honours and awards from DPhG, APS and Galenus Foundation. Carsten actively serves on the Editorial Boards of the American Journal of Physiology - Lung Cellular and Molecular Physiology, Drug Delivery Letters, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Journal of Pharmaceutical Sciences and European Journal of Pharmaceutics and Biopharmaceutics.
  • Paul Johnson
    Director Pau Johnson Consulting Limited
    Paul Johnson is a pharmaceutical development consultant, specialising in inhaled medicines with over 30 years\' experience in the industry at blue chip companies. In the late 1990s he was leading the pharmaceutical re-development of a pMDI asset switching from propellant CFC 11/12 to HFA-134a and led GSK\'s novel pMDI technology efforts (generating a number of patents). In the early 2000s, Paul focus shifted from line extensions to bringing forward many of GSKs early development respiratory projects. He had the unique experience of leading the development of a portfolio of GSK inhaled NCEs and the associated novel delivery platform (Ellipta) from pre-candidate selection through to launch and lifecycle management. Post his work on Ellipta, Paul was able to seek and incubate several novel delivery systems to provide future platforms for GSKs respiratory products. He is a CMC expert with special expertise in inhaled delivery systems and products who regularly partners with clinical, regulatory and commercial leaders, to shape and execute the overall drug development, manufacture and launch strategy.
  • Prof, Dr. Sven Stegemann
  • Iris Erez
    Director of respiratory segment
  • Christina Gkousgkouni
  • Wilbur de Kruijf
    Wilbur de Kruijf is responsible for new business development at Medspray Pharma BV, the Netherlands. Medspray Pharma develops novel metered dose liquid inhalers and eye spray devices, based on their proprietary micro nano technology spray nozzles. Wilbur joined Medspray eleven years ago to start up device development in collaboration with Medspray’s device partners. Wilbur (born in 1971) has a background in Industrial Design Engineering (M.Sc. Design Engineering 1995, M.Sc. Advanced Industrial Design Engineering 1997, Delft University of Technology) with further specialization in medical device development (acc. ISO 13485), design for six sigma and user-centered design. Before joining Medspray, Wilbur worked almost 10 years for a Dutch design consultancy firm, Indes, winning several international design and usability awards for homecare & rehab products and hospital equipment. Wilbur is a member of the IPAC-RS consortium’s device work group, he is the secretary of the Dutch medical aerosol scientist network ‘MAD Foundation’ and he is active in the COST Action SimInhale
  • Dr. Frank Thielmann
    Dr Thielmann graduated from University of Duesseldorf, Germany in 1996 with a diploma in Chemistry. This was followed by a PhD in Physical Chemistry in 1998 in the area of materials characterisation. Frank then worked for a private materials testing institute in Hannover, Germany before joining Surface Measurement Systems UK (SMS) in 2000. He stayed with SMS for eight years in different roles including global Head of Application Science. In this role, he was heavily involved in the development of novel characterisation methods for the challenges in the modern (bio)pharmaceutical industry with focus on solid dosage forms. Frank joined Novartis Pharma (Basel, Switzerland) in July 2007 as Formulation Lab Head. From August 2009 until February 2011 he managed the inhalation & device development group at the Horsham site, UK. Upon his return to Basel he took on the responsibility for the local inhalation technology platform until February 2012. Subsequently he joined Novartis Technical Operations where he was leading the setup of a new inhalation manufacturing facility and the transfer of the corresponding portfolio. In December 2016 Frank joint the Biologics Technical Development & Manufacturing department as the Lead for PMO & Operational Excellence. Dr Thielmann is member of the Steering Committee of the Material Science Focus Group in the British Academy of Pharmaceutical Sciences. He is an author and co-author of more than 25 articles in peer reviewed journals as well as author and co-author of more than 50 oral presentations at international conferences and seminars and over 100 scientific posters.
  • Dr. Joachim Eicher
    Boehringer Ingelheim
Buy Ticket